# Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

> **NCT03627299** · PHASE4 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 11 (actual)

## Conditions studied

- End Stage Renal Disease
- Hepatitis C

## Interventions

- **DRUG:** 300mg glecaprevir/pibrentasivir 120mg

## Key facts

- **NCT ID:** NCT03627299
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2019-12-19
- **Final completion:** 2021-09-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627299, "Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03627299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*